• Je něco špatně v tomto záznamu ?

Antisense oligonucleotides as a targeted therapeutic approach in model of acute myeloid leukemia

D. Macečková, L. Vaňková, J. Bufka, P. Hošek, J. Moravec, P. Pitule

. 2024 ; 52 (1) : 57. [pub] 20241218

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003016

Grantová podpora
260 651 SVV - Specifický vysokoškolský výzkum
350322 GAUK - Grantová agentura Univerzity Karlovy
LX22NPO5102 NICR - The project National Institute for Cancer Research EXCELES

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 39692897
DOI 10.1007/s11033-024-10172-w
Knihovny.cz E-zdroje

BACKGROUND: The genetic and epigenetic alterations observed in acute myeloid leukemia (AML) contribute to its heterogeneity, influencing disease progression response to therapy, and patient outcomes. The use of antisense oligonucleotides (ASOs) technology allows for the design of oligonucleotide inhibitors based on gene sequence information alone, enabling precise targeting of key molecular pathways or specific genes implicated in AML. METHODS AND RESULTS: Midostaurin, a FLT3 specific inhibitor and ASOs targeting particular genes, exons, or mutations was conducted using AML models. This ASOs treatment was designed to bind to exon 7 of the MBNL1 (muscleblind-like) gene. Another target was the FLT3 gene, focusing on two aspects: (a) FLT3-ITD (internal tandem duplication), to inhibit the expression of this aberrant gene form, and (b) the FLT3 in general. Treated and untreated cells were analyzed using quantitative PCR (qPCR), dot blot, and Raman spectroscopy. This study contrasts midostaurin with ASOs that inhibit FLT3 protein production or its isoforms via mRNA degradation. A trend of increased FLT3 expression was observed in midostaurin-treated cells, while ASO-treated cells showed decreased expression, though these changes were not statistically significant. CONCLUSIONS: In AML, exon 7 of MBNL1 is involved in several cellular processes and in this study, exon 7 of MBNL1 was targeted for method optimization, with the highest block of the exon 7 gene variant observed 48 h post-transfection. Midostaurin, a multitargeted kinase inhibitor, acts against the receptor tyrosine kinase FLT3, a critical molecule in AML pathogenesis. While midostaurin blocks FLT3 signaling pathways, it paradoxically increases FLT3 expression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003016
003      
CZ-PrNML
005      
20250206104015.0
007      
ta
008      
250121s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11033-024-10172-w $2 doi
035    __
$a (PubMed)39692897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Macečková, Diana $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia. maceckod@lfp.cuni.cz $u Laboratory of Tumor Biology and Immunotherapy Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, Pilsen, 32300, Czech Republic. maceckod@lfp.cuni.cz
245    10
$a Antisense oligonucleotides as a targeted therapeutic approach in model of acute myeloid leukemia / $c D. Macečková, L. Vaňková, J. Bufka, P. Hošek, J. Moravec, P. Pitule
520    9_
$a BACKGROUND: The genetic and epigenetic alterations observed in acute myeloid leukemia (AML) contribute to its heterogeneity, influencing disease progression response to therapy, and patient outcomes. The use of antisense oligonucleotides (ASOs) technology allows for the design of oligonucleotide inhibitors based on gene sequence information alone, enabling precise targeting of key molecular pathways or specific genes implicated in AML. METHODS AND RESULTS: Midostaurin, a FLT3 specific inhibitor and ASOs targeting particular genes, exons, or mutations was conducted using AML models. This ASOs treatment was designed to bind to exon 7 of the MBNL1 (muscleblind-like) gene. Another target was the FLT3 gene, focusing on two aspects: (a) FLT3-ITD (internal tandem duplication), to inhibit the expression of this aberrant gene form, and (b) the FLT3 in general. Treated and untreated cells were analyzed using quantitative PCR (qPCR), dot blot, and Raman spectroscopy. This study contrasts midostaurin with ASOs that inhibit FLT3 protein production or its isoforms via mRNA degradation. A trend of increased FLT3 expression was observed in midostaurin-treated cells, while ASO-treated cells showed decreased expression, though these changes were not statistically significant. CONCLUSIONS: In AML, exon 7 of MBNL1 is involved in several cellular processes and in this study, exon 7 of MBNL1 was targeted for method optimization, with the highest block of the exon 7 gene variant observed 48 h post-transfection. Midostaurin, a multitargeted kinase inhibitor, acts against the receptor tyrosine kinase FLT3, a critical molecule in AML pathogenesis. While midostaurin blocks FLT3 signaling pathways, it paradoxically increases FLT3 expression.
650    12
$a akutní myeloidní leukemie $x genetika $x farmakoterapie $7 D015470
650    _2
$a lidé $7 D006801
650    12
$a tyrosinkinasa 3 podobná fms $x genetika $x antagonisté a inhibitory $x metabolismus $7 D051941
650    12
$a staurosporin $x analogy a deriváty $x farmakologie $7 D019311
650    12
$a antisense oligonukleotidy $x farmakologie $x genetika $7 D016376
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proteiny vázající RNA $x genetika $x metabolismus $7 D016601
650    _2
$a exony $x genetika $7 D005091
650    _2
$a regulace genové exprese u leukemie $x účinky léků $7 D015973
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vaňková, Lenka $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Bufka, Jiří $u Department of Pediatrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Pilsen, Czechia
700    1_
$a Hošek, Petr $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Moravec, Jiří $u Laboratory of Proteomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Pitule, Pavel $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
773    0_
$w MED00003392 $t Molecular biology reports $x 1573-4978 $g Roč. 52, č. 1 (2024), s. 57
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39692897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104011 $b ABA008
999    __
$a ok $b bmc $g 2263042 $s 1239023
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 52 $c 1 $d 57 $e 20241218 $i 1573-4978 $m Molecular biology reports $n Mol Biol Rep $x MED00003392
GRA    __
$a 260 651 $p SVV - Specifický vysokoškolský výzkum
GRA    __
$a 350322 $p GAUK - Grantová agentura Univerzity Karlovy
GRA    __
$a LX22NPO5102 $p NICR - The project National Institute for Cancer Research EXCELES
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace